Vytacera Pharma

Vytacera Pharma is a pre-clinical stage biotechnology company specializing in the field of targeted protein degradation (TPD). The company utilizes its proprietary Vytacera platform to develop small molecule therapeutics, including PROTACs and molecular glues, designed to eliminate disease-causing proteins that are otherwise difficult to target with traditional inhibitors. Spun out of research from the University of Southern California, Vytacera focuses primarily on oncology and other areas of high unmet medical need. Their approach aims to provide more durable and potent responses by leveraging the body's natural protein disposal system. The company is currently optimizing lead candidates for various solid tumor indications.